Fleischmann R, Nagy O, Ren J, Mysler E, et al. Response to correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH stud Ann Rheum Dis 2026 Jun 12:S0003-4967(26)00304-3. doi: 10.1016/j.ard.2026.
PMID: 42285872